TrialJectory (“the Company”), announced today results from a proprietary survey highlighting that, while an overwhelming majority of cancer patients surveyed (90 percent) understand the importance of genetic testing for achieving better clinical outcomes, less than half (46 percent) reported having undergone Next-Generation Sequencing (NGS),
| NEW YORK, Aug. 18, 2021 /PRNewswire/ -- TrialJectory (“the Company”), an AI-powered, decision-making platform that connects cancer patients to advanced treatment options and helps to accelerate clinical research timelines, announced today results from a proprietary survey highlighting that, while an overwhelming majority of cancer patients surveyed (90 percent) understand the importance of genetic testing for achieving better clinical outcomes, less than half (46 percent) reported having undergone Next-Generation Sequencing (NGS), a genetic test used to identify novel cancer mutations and familial cancer mutation carriers. “While the healthcare industry preaches the power of precision medicine, the reality is that access to advanced treatments remains largely out of reach for many cancer patients, simply because they don’t undergo Next-Generation Sequencing, a U.S. National Comprehensive Cancer Network Guidelines recommendation,” said Tzvia Bader, Co-Founder and TrialJectory CEO. “For the medical community to be true patient advocates, it needs to empower patients and their families to make more informed decisions. This begins with facilitating easy access to genetic testing. Now is the time to remove the artificial barriers currently standing in the way of providing cancer patients with the access they need to take advantage of advanced precision medicine.” NGS testing is used to advance personalized cancer treatment and has proven in recent years to be a sound method for effectively capturing a large amount of genomic information about cancer. NGS testing can shed significant light on complex treatment decisions to put patients on the right treatment courses based on their unique genomic makeup. This, in turn, leads to better clinical outcomes. However, despite the fact that NGS data capabilities can drive better outcomes, there is a clear lack of emphasis from the healthcare industry to actively recommend and encourage patients to undergo this testing. “With all of the advancements that have been made with precision medicine, specifically within cancer, it is unconscionable for the healthcare industry to stand in the way of patients gaining access to lifesaving treatments,” Bader continued. “The COVID pandemic has proven both the need for, and increasing demand of, patients to control their own cancer journey. By allowing access to genetic testing, we will ultimately save lives. NGS testing empowers physicians and patients to make more informed decisions relevant to specific diagnoses and courses of treatment to achieve better outcomes.” About TrialJectory TrialJectory is a patient-first digital health company with a mission to democratize access to advanced cancer treatment. Recognized by TIME as one of “The 100 Best Inventions of 2020” and named an honoree in the AI and data category for Fast Company‘s “2021 World Changing Ideas Awards,” TrialJectory uses artificial intelligence (AI) to inform and empower cancer patients to own their treatment journey. The only offering of its kind, TrialJectory also captures and analyzes real-world patient data that can be used to further evolve the oncology research landscape. For more information, please visit www.trialjectory.com, and follow the Company on Facebook and LinkedIn.
SOURCE TrialJectory |
View original content:
